According to the Website the Company Completed a Phase 2 Clinical Trial. Any idea of how long ago it completed the Phase 2? thx. BTW, 475A/S not bad. seems that LJCI though "owns" the Company. Company lists its Corporate HQ and R&D as a Suite 301. I take it the Company Outsources its investigational science to Colleges and 3rd Partys? Do you know how many Employees the Companys has full time and how many are scienctists? 5million market cap is appeailing, even though the company is in a spiral of debt to LJCI, i am very curious about the Phase 2 and when it was completed for the MCT-125. Phase 3's are very expensive. Company does not ahve the cash according to finanicals.
The Company’s first-in-class therapeutic pipeline includes:
•MCT-125 for the treatment of chronic fatigue in MS patients. MCT-125 completed a 138 patient Phase II clinical trial and demonstrated strong efficacy in reducing fatigue in MS patients. There is no drug specifically approved for the treatment of chronic fatigue in MS patients anywhere in the world.
News 
Market Data 
Discover 
